Search

Your search keyword '"Lee, Mei-Hsuan"' showing total 218 results
Start Over Author "Lee, Mei-Hsuan" Search Limiters Academic (Peer-Reviewed) Journals
218 results on '"Lee, Mei-Hsuan"'

1. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan

Author

Yang, Chun-Chi, Huang, Chung-Feng, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Kuo, Hsing-Tao, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Tseng, Kuo-Chih, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2024
Full Text
View/download PDF

3. Novel lissencephaly-associated NDEL1 variant reveals distinct roles of NDE1 and NDEL1 in nucleokinesis and human cortical malformations

Author

Tsai, Meng-Han, Ke, Hao-Chen, Lin, Wan-Cian, Nian, Fang-Shin, Huang, Chia-Wei, Cheng, Haw-Yuan, Hsu, Chi-Sin, Granata, Tiziana, Chang, Chien-Hui, Castellotti, Barbara, Lin, Shin-Yi, Doniselli, Fabio M., Lu, Cheng-Ju, Franceschetti, Silvana, Ragona, Francesca, Hou, Pei-Shan, Canafoglia, Laura, Tung, Chien-Yi, Lee, Mei-Hsuan, Wang, Won-Jing, and Tsai, Jin-Wu

Published
2024
Full Text
View/download PDF

5. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

Author

Chang, Te-Sheng, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, Hung, Chao-Hung, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

6. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study

Author

Chan, Chang-Chuan, Chan, Si-Wa, Chang, I-Shou, Chang, Jer-Hwa, Chao, Kun-San, Chen, Chi-Jen, Chen, Huei-Wen, Chiang, Chun-Ju, Chiou, Hung-Yi, Chou, Mei-Chun, Chung, Chi-Li, Chung, Ta-Jung, Guo, Yue Leon, Hsiao, Chin-Fu, Huang, Chien-Sheng, Ko, Sheung-Fat, Lee, Mei-Hsuan, Li, Yao-Jen, Liao, Yu-San, Lu, Yueh-Hsun, Ou, Hsin-You, Wu, Ping-An, Yang, Hwai-I, Yang, Shi-Yi, Yang, Szu-Chun, Chang, Gee-Chen, Chiu, Chao-Hua, Yu, Chong-Jen, Chang, Yeun-Chung, Chang, Ya-Hsuan, Hsu, Kuo-Hsuan, Wu, Yu-Chung, Chen, Chih-Yi, Hsu, Hsian-He, Wu, Ming-Ting, Yang, Cheng-Ta, Chong, Inn-Wen, Lin, Yu-Ching, Hsia, Te-Chun, Lin, Meng-Chih, Su, Wu-Chou, Lin, Chih-Bin, Lee, Kang-Yun, Wei, Yu-Feng, Lan, Gong-Yau, Chan, Wing P, Wang, Kao-Lun, Wu, Mei-Han, Tsai, Hao-Hung, Chian, Chih-Feng, Lai, Ruay-Sheng, Shih, Jin-Yuan, Wang, Chi-Liang, Hsu, Jui-Sheng, Chen, Kun-Chieh, Chen, Chun-Ku, Hsia, Jiun-Yi, Peng, Chung-Kan, Tang, En-Kuei, Hsu, Chia-Lin, Chou, Teh-Ying, Shen, Wei-Chih, Tsai, Ying-Huang, Tsai, Chun-Ming, Chen, Yuh-Min, Lee, Yu-Chin, Chen, Hsuan-Yu, Yu, Sung-Liang, Chen, Chien-Jen, Wan, Yung-Liang, Hsiung, Chao Agnes, and Yang, Pan-Chyr

Published
2024
Full Text
View/download PDF

7. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie

Published
2023
Full Text
View/download PDF

8. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

Author

Razavi, Homie A., Buti, Maria, Terrault, Norah A., Zeuzem, Stefan, Yurdaydin, Cihan, Tanaka, Junko, Aghemo, Alessio, Akarca, Ulus S., Al Masri, Nasser M., Alalwan, Abduljaleel M., Aleman, Soo, Alghamdi, Abdullah S., Alghamdi, Saad, Al-Hamoudi, Waleed K., Aljumah, Abdulrahman A., Altraif, Ibrahim H., Asselah, Tarik, Ben-Ari, Ziv, Berg, Thomas, Biondi, Mia J., Blach, Sarah, Braga, Wornei S.M., Brandão-Mello, Carlos E., Brunetto, Maurizia R., Cabezas, Joaquin, Cheinquer, Hugo, Chen, Pei-Jer, Cheon, Myeong-Eun, Chuang, Wan-Long, Coffin, Carla S., Coppola, Nicola, Craxi, Antonio, Crespo, Javier, De Ledinghen, Victor, Duberg, Ann-Sofi, Etzion, Ohad, Ferraz, Maria Lucia G., Ferreira, Paulo R.A., Forns, Xavier, Foster, Graham R., Gaeta, Giovanni B., Gamkrelidze, Ivane, García-Samaniego, Javier, Gheorghe, Liliana S., Gholam, Pierre M., Gish, Robert G., Glenn, Jeffrey, Hercun, Julian, Hsu, Yao-Chun, Hu, Ching-Chih, Huang, Jee-Fu, Janjua, Naveed, Jia, Jidong, Kåberg, Martin, Kaita, Kelly D.E., Kamal, Habiba, Kao, Jia-Horng, Kondili, Loreta A., Lagging, Martin, Lázaro, Pablo, Lazarus, Jeffrey V., Lee, Mei-Hsuan, Lim, Young-Suk, Marotta, Paul J., Navas, Maria-Cristina, Naveira, Marcelo C.M., Orrego, Mauricio, Osiowy, Carla, Pan, Calvin Q., Pessoa, Mário G., Raimondo, Giovanni, Ramji, Alnoor, Razavi-Shearer, Devin M., Razavi-Shearer, Kathryn, Ríos-Hincapié, Cielo Y., Rodríguez, Manuel, Rosenberg, William M.C., Roulot, Dominique M., Ryder, Stephen D., Safadi, Rifaat, Sanai, Faisal M., Santantonio, Teresa A., Sarrazin, Christoph, Shouval, Daniel, Tacke, Frank, Tergast, Tammo L., Villalobos-Salcedo, Juan Miguel, Voeller, Alexis S., Yang, Hwai-I, Yu, Ming-Lung, and Zuckerman, Eli

Published
2023
Full Text
View/download PDF

12. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan

Author

Lo, Ching-Chu, Huang, Chung-Feng, Cheng, Pin-Nan, Tseng, Kuo-Chih, Chen, Chi-Yi, Kuo, Hsing-Tao, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Chen, Chun-Ting, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Mo, Lein-Ray, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Hsiung, Chou-Kwok, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Liu, Chun-Jen, Dai, Chia-Yen, Chuang, Wan-Long, Lin, Han-Chieh, Kao, Jia-Horng, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

13. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

Author

Blach, Sarah, Terrault, Norah A, Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J, Abbas, Zaigham, Abdallah, Ayat R, Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S, Alalwan, Abduljaleel M, Alanko Blomé, Marianne, Al-Busafi, Said A, Aleman, Soo, Alghamdi, Abdullah S, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Al-Naamani, Khalid, Al Serkal, Yousif M, Altraif, Ibrahim H, Anand, Anil C, Anderson, Motswedi, Andersson, Monique I, Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R, Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J, Bizri, Abdul Rahman N, Brandão-Mello, Carlos E, Brigida, Krestina, Brown, Kimberly A, Brown, Jr, Robert S, Bruggmann, Philip, Brunetto, Maurizia R, Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Chien, Rong-Nan, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura E, Coco, Barbara, Contreras, Fernando A, Cornberg, Markus, Cramp, Matthew E, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris W, Dagher Abou, Lucy, Dalgard, Olav, Dao, Doan Y, De Ledinghen, Victor, Derbala, Moutaz F, Deuba, Keshab, Dhindsa, Karan, Djauzi, Samsuridjal, Drazilova, Sylvia, Duberg, Ann-Sofi, Elbadri, Mohammed, El-Sayed, Manal H, Esmat, Gamal, Estes, Chris, Ezzat, Sameera, Färkkilä, Martti A, Ferradini, Laurent, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Filipec Kanizaj, Tajana, Flisiak, Robert, Frankova, Sona, Fung, James, Gamkrelidze, Amiran, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana S, Gholam, Pierre M, Goldis, Adrian, Gottfredsson, Magnus, Gray, Richard T, Grebely, Jason, Gschwantler, Michael, Hajarizadeh, Behzad, Hamid, Saeed S, Hamoudi, Waseem, Hatzakis, Angelos, Hellard, Margaret E, Himatt, Sayed, Hofer, Harald, Hrstic, Irena, Hunyady, Bela, Husa, Petr, Husic-Selimovic, Azra, Jafri, Wasim S M, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jerkeman, Anna, Jeruma, Agita, Jia, Jidong, Jonasson, Jon G, Kåberg, Martin, Kaita, Kelly D E, Kaliaskarova, Kulpash S, Kao, Jia-Horng, Kasymov, Omor T, Kelly-Hanku, Angela, Khamis, Faryal, Khamis, Jawad, Khan, Aamir G, Khandu, Lekey, Khoudri, Ibtissam, Kielland, Knut B, Kim, Do Young, Kodjoh, Nicolas, Kondili, Loreta A, Krajden, Mel, Krarup, Henrik Bygum, Kristian, Pavol, Kwon, Jisoo A, Lagging, Martin, Laleman, Wim, Lao, Wai Cheung, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice U, Lee, Mei-Hsuan, Li, Michael K K, Liakina, Valentina, Lim, Young-Suk, Löve, Arthur, Lukšić, Boris, Machekera, Shepherd Mufudzi, Malu, Abraham O, Marinho, Rui T, Maticic, Mojca, Mekonnen, Hailemichael D, Mendes-Correa, Maria Cássia, Mendez-Sanchez, Nahum, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mills, Mike, Mohamed, Rosmawati, Mooneyhan, Ellen, Moreno, Christophe, Muljono, David H, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Nartey, Yvonne Ayerki, Naveira, Marcelo C M, Negro, Francesco, Nersesov, Alexander V, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin S, Obekpa, Solomon A, Oguche, Stephen, Olafsson, Sigurdur, Ong, Janus P, Opare-Sem, Ohene K, Orrego, Mauricio, Øvrehus, Anne L, Pan, Calvin Q, Papatheodoridis, George V, Peck-Radosavljevic, Markus, Pessoa, Mário G, Phillips, Richard O, Pimenov, Nikolay, Plaseska-Karanfilska, Dijana, Prabdial-Sing, Nishi N, Puri, Pankaj, Qureshi, Huma, Rahman, Aninda, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo Y, Rizvi, S M Shahriar, Robaeys, Geert K M M, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa S, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek A, Sarrazin, Christoph, Sarybayeva, Gulya, Seguin-Devaux, Carole, Sharara, Ala I, Sheikh, Mahdi, Shewaye, Abate B, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta Y, Sonderup, Mark W, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf E, Stedman, Catherine A M, Su, Tung-Hung, Suleiman, Anita, Sypsa, Vana, Tamayo Antabak, Natalia, Tan, Soek-Siam, Tergast, Tammo L, Thurairajah, Prem H, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsereteli, Maia, Uzochukwu, Benjamin S C, Van De Vijver, David A M C, Van Santen, Daniela K, Van Vlierberghe, Hans, Van Welzen, Berend, Vanwolleghem, Thomas, Vélez-Möller, Patricia, Villamil, Federico, Vince, Adriana, Waheed, Yasir, Weis, Nina, Wong, Vincent W-S, Yaghi, Cesar G, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yunihastuti, Evy, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie A

Published
2022
Full Text
View/download PDF

14. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)

Author

Huang, Chung-Feng, Tseng, Kuo-Chih, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Peng, Cheng-Yuan, Bair, Ming-Jong, Yeh, Ming-Lun, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Chuang, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

15. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Author

Cheng, Pin-Nan, Mo, Lein-Ray, Chen, Chun-Ting, Chen, Chi-Yi, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Tseng, Kuo-Chih, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Chou, Kwok-Hsiung, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Cheng, Chien-Yu, Tsai, Ming-Chang, Liu, Chun-Jen, Dai, Chia-Yen, Lin, Han-Chieh, Kao, Jia-Horng, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

17. The efficacy of multi‐disciplinary lifestyle modifications in Taiwanese nonalcoholic steatohepatitis patients.

Author

Yeh, Ming‐Lun, Dai, Chia‐Yen, Huang, Chung‐Feng, Huang, Shiu‐Feng, Tsai, Pei‐Chien, Hsu, Po‐Yau, Huang, Ching‐I, Wei, Yu‐Ju, Liang, Po‐Cheng, Bair, Ming‐Jong, Lee, Mei‐Hsuan, Lin, Zu‐Yau, Huang, Jee‐Fu, Yu, Ming‐Lung, and Chuang, Wan‐Long

Subjects
NON-alcoholic fatty liver disease, WEIGHT loss, FATTY liver, BLOOD sugar
Abstract

Lifestyle modification is the standard of care for nonalcoholic fatty liver disease (NAFLD) patients. We aimed to investigate the efficacy of a short‐term lifestyle modification program in the disease course of Taiwanese nonalcoholic steatohepatitis (NASH) patients with paired biopsies. All patients received a 6‐month, strict multidisciplinary program of lifestyle modifications led by physicians, dieticians, and nursing staff. The histopathological and clinical features were assessed. The endpoints were normalization of transaminase levels, metabolic parameters, a decrease in the NAFLD activity score (NAS) ≥1, and a decrease in the fibrosis stage ≥1. We also aimed to elucidate the predictors associated with disease progression. A total of 37 patients with biopsy‐proven NASH were enrolled. The normalization of transaminase levels increased from 0% to 13.5%. There were also significantly increased proportions of patients with normal total cholesterol, triglyceride, and hemoglobin A1c levels. Fifteen (40.5%) patients had an increased NAS ≥1, whereas 10 (27.0%) patients had NAS regression. Twelve (32.4%) patients had increased fibrosis ≥1 stage. Only 2 (5.4%) patients experienced fibrosis regression. A high fasting plasma glucose (FPG) level was associated with NAS progression. Older age and higher transaminase and FPG levels were factors associated with fibrosis progression. Seven (18.9%) patients achieved a body weight reduction >3%, and 4 (57.1%) of them experienced NAS regression. No significant effect of weight reduction on the progression of fibrosis was observed. The short‐term lifestyle modification program significantly decreased liver enzymes and metabolic parameters in NASH patients. A more precise or intensive program may be needed for fibrosis improvement. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung.

Author

Kuo, Chia‐Yu, Tsai, Ming‐Ju, Hung, Jen‐Yu, Lee, Mei‐Hsuan, Wu, Kuan‐Li, Tsai, Yu‐Chen, Chuang, Cheng‐Hao, Huang, Chung‐Wen, Chen, Chin‐Ling, Yang, Chih‐Jen, and Chong, Inn‐Wen

Subjects
EPIDERMAL growth factor receptors, PROTEIN-tyrosine kinase inhibitors, VASCULAR endothelial growth factors, ERLOTINIB, PEMETREXED, BEVACIZUMAB, PROGRESSION-free survival
Abstract

Combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an anti‐ vascular endothelial growth factor (VEGF) agent, bevacizumab or ramucirumab, is indicated for advanced lung adenocarcinoma harboring EGFR mutation. This study aimed to show the real‐world data of combination therapy and compare the effectiveness between bevacizumab and ramucirumab in combination with an EGFR‐TKI. This retrospective study enrolled 47 patients diagnosed of stage IV lung adenocarcinoma with exon 19 deletion or L858R point mutation, receiving a first‐line EGFR‐TKI with anti‐VEGF agent, including 34 (72%) and 13 (28%) patients receiving bevacizumab and ramucirumab, respectively. The response rate was similar in both groups (p = 0.38). Patients receiving bevacizumab had similar progression free survival (PFS) as those receiving ramucirumab (median PFS: 21.9 vs. 24.2 months, p = 0.4871); similar finding was noted in overall survival (OS) (median OS: 33.5 months vs. not reached, p = 0.4618). Patients receiving ramucirumab experienced a significantly high‐grade hypertension compared to those receiving bevacizumab (p = 0.0351). Multivariable Cox regression analysis found independent risk factors for worse PFS included poorer ECOG performance status, multiple (≥3) metastatic sites, brain metastasis, and pleural metastasis/effusion, while the type of anti‐VEGF agent was not a risk factor. Pericardial metastasis/effusion was the only one independent risk factor for worse OS. In summary, ramucirumab may have similar effectiveness as bevacizumab in combination with an EGFR‐TKI as first line therapy for advanced lung adenocarcinoma harboring susceptible EGFR mutation. Further large‐scale registry‐based cohort studies may be needed to validate our findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.

Author

Lin, Hsin‐Che, Jeng, Wen‐Juei, Liu, Jessica, Pan, Mei‐Hung, Lee, Mei‐Hsuan, Batrla‐Utermann, Richard, Lu, Sheng‐Nan, Chen, Chuen‐Fei, Yang, Hwai‐I., and Chen, Chien‐Jen

Subjects
CHRONIC hepatitis B, HEPATITIS associated antigen, HEPATOCELLULAR carcinoma
Abstract

Summary: Background: High hepatitis B surface antigen (HBsAg) level predicts hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with low viral load. The role of longitudinal HBsAg levels in predicting HCC in HBeAg‐positive CHB patients remains unknown. Method: HBeAg‐positive CHB participants from the REVEAL‐HBV cohort with ≥2 HBsAg measurements before HBeAg seroclearance were enrolled. Group‐based trajectory modelling identified distinct HBsAg trajectory groups during a median of 11 years of HBeAg‐positive status. Cox regression models were applied for investigating independent predictors of HCC and estimating adjusted hazard ratio (HRadj) with a 95% confidence interval (CI). A p‐value less than 0.05 was considered statistically significant. Results: A total of 319 patients were enrolled and classified by HBsAg trajectory patterns as (A) persistently high group (n = 72): HBsAg persistently ≥104 IU/mL, and (B) non‐stationary group (n = 233): low HBsAg at baseline or declining to <104 IU/mL during the follow‐up. Group B had higher proportions of abnormal ALT levels, HBV genotype C and basal core mutation than group A (p < 0.05); age at entry and gender were comparable. The annual incidence of HCC in group A and group B were 0.37% and 1.16%, respectively (p = 0.03). In multivariate analysis, age >40 years (HRadj [95% CI] = 4.11 [2.26–7.48]), genotype C (HRadj [95% CI] = 4.39 [1.96–9.81]) and the non‐stationary group (HRadj [95% CI] = 3.50 [1.49–8.21]) were independent predictors of HCC. Basal core promoter mutation was the only risk factor of HCC in the persistently high HBsAg group (HRadj [95% CI] = 32.75 [5.41–198.42]). Conclusion: Patients with persistently high HBsAg levels during HBeAg‐seropositive stage represent a unique population with low risk of HCC development. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients.

Author

Lai, Jiun-I, Kuo, Ting-Hao, Huang, Kuan-Jung, Chai, Laura Min Xuan, Lee, Mei-Hsuan, Liu, Chun-Yu, Tsai, Yi-Fang, Huang, Chi-Cheng, Tseng, Ling-Ming, Hsu, Cheng-Chih, and Chao, Ta-Chung

Subjects
PERITONEAL dialysis, PROTEIN-tyrosine kinase inhibitors, BREAST tumors, DRUG administration, SEVERITY of illness index, RETROSPECTIVE studies, TREATMENT effectiveness, DESCRIPTIVE statistics, GAS chromatography, MASS spectrometry, PHARMACOKINETICS, PROGRESSION-free survival, GENOTYPES, NEUTROPENIA, CYCLIN-dependent kinases, GENOMES, CHEMICAL inhibitors
Abstract

Background CDK4/6 inhibitors (CDK4/6i) have shown great efficacy in prolonging progression-free survival and is the current standard of care for hormone positive (HR(+)) metastatic breast cancer (mBC). Despite well tolerability and ease of use, the most common side effect of CDK4/6i is myelosuppression, with neutropenia the most prevalent adverse effect. Studies show that the prevalence and severity of neutropenia are more marked in Asian patients, although details remain obscure. Methods In this study, we retrospectively analyzed 105 Taiwanese patients who received palbociclib for HR(+) HER2(−) mBC at the Taipei Veterans General Hospital. To investigate a possible genetic association for high prevalence of neutropenia, we queried the Taiwan Biobank with publicly available germline databases (ALFA, gnomAD, ExAC, 1000 Genomes project, HapMap), for the allele frequencies of 4 neutropenia-related SNPs (ABCB1_rs1045642, ABCB1_rs1128503, ERCC1_rs3212986, ERCC1_rs11615) and compared between different ethnicities. In addition, one of the patients was a long-term patient with peritoneal dialysis. We quantified the levels of palbociclib in her serum and peritoneal fluid by liquid chromatography-mass spectrometry (LC-MS). Results Interestingly, in our cohort, early neutropenia nadir (occurred within 56 days of start) was associated with worse treatment outcome, while occurrence of grade 3/4 neutropenia was associated with better outcome. We observed an extremely high incidence of neutropenia (96.2% any grade, 70.4% grade 3/4). In the analyzed germline databases, we discovered a higher SNP frequency of the T allele in ABCB1_rs1128503, a lower frequency of T allele in ABCB1_rs1045642, and a higher SNP frequency of G allele in ERCC1_rs11615. We observed that palbociclib levels in peritoneal dialysate ranged from around 20-50 ppb, and serum levels reached 100-110 ppb during drug administration and decreased to <10 ppb during discontinuation. Conclusion Our retrospective analysis of real world palbociclib use reveals an association with grade 3/4 neutropenia with better outcome and early neutropenia nadir with worse outcome. Our findings of Asian specific SNPs support a predisposition toward profound and prevalent neutropenia in Asian patients under CDK4/6i. We also report the first pharmacokinetics analysis on a patient with peritoneal dialysis receiving CDK4/6i. In summary, our study provides novel clinical and genotypic insights into CDK4/6i associated neutropenia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

28. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Nguyen, Mindie H, Chen, Ding-Shinn, Van Damme, Pierre, Abbas, Zaigham, Abdulla, Maheeba, Abou Rached, Antoine, Adda, Danjuma, Aho, Inka, Akarca, Ulus, Hasan, Fuad, Al Lawati, Faryal, Al Naamani, Khalid, Al-Ashgar, Hamad Ibrahim, Alavian, Seyed M, Alawadhi, Sameer, Albillos, Agustin, Al-Busafi, Said A, Aleman, Soo, Alfaleh, Faleh Z, Aljumah, Abdulrahman A, Anand, Anil C, Anh, Nguyen Thu, Arends, Joop E, Arkkila, Perttu, Athanasakis, Kostas, Bane, Abate, Ben-Ari, Ziv, Berg, Thomas, Bizri, Abdul R, Blach, Sarah, Brandão Mello, Carlos E, Brandon, Samantha M, Bright, Bisi, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Chan, Henry L Y, Chaudhry, Asad, Chien, Rong-Nan, Choi, Moon S, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Clausen, Mette R, Colombo, Massimo, Cornberg, Markus, Cowie, Benjamin, Craxi, Antonio, Croes, Esther A, Cuellar, Diego Alberto, Cunningham, Chris, Desalegn, Hailemichael, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve S, El-Sayed, Manal H, Estes, Chris, Falconer, Karolin, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gaeta, Giovanni B, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Goldis, Adrian, Gountas, Ilias, Gray, Richard, Guimarães Pessôa, Mário, Hajarizadeh, Behzad, Hatzakis, Angelos, Hézode, Christophe, Himatt, Sayed M, Hoepelman, Andy, Hrstic, Irena, Hui, Yee-Tak T, Husa, Petr, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jaroszewicz, Jerzy, Kaymakoglu, Sabahattin, Kershenobich, David, Kondili, Loreta A, Konysbekova, Aliya, Krajden, Mel, Kristian, Pavol, Laleman, Wim, Lao, Wai-cheung C, Layden, Jen, Lazarus, Jeffrey V, Lee, Mei-Hsuan, Liakina, Valentina, Lim, Young-Suk S, Loo, Ching-kong K, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham O, Mamatkulov, Adkhamjon, Manns, Michael, Marinho, Rui T, Maticic, Mojca, Mauss, Stefan, Memon, Muhammad S, Mendes Correa, Maria C, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Mokhbat, Jacques E, Moreno, Christophe, Mossong, Joel, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Musabaev, Erkin, Nawaz, Arif, Nde, Helen M, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Njouom, Richard, Ntagirabiri, Renovat, Nurmatov, Zuridin, Obekpa, Solomon, Ocama, Ponsiano, Oguche, Stephen, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Opio, Christopher K, Örmeci, Necati, Papatheodoridis, George, Pasini, Ken, Pimenov, Nikolay, Poustchi, Hossein, Quang, Trân D, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Rios, Cielo Yaneth, Rjaskova, Gabriela, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Scott, Julia, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shiha, Gamal E, Shin, Tesia, Sievert, William, Sperl, Jan, Stärkel, Peter, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek S, Tanaka, Junko, Tomasiewicz, Krzysztof, Urbanek, Petr, van der Meer, Adriaan J, Van Vlierberghe, Hans, Vella, Stefano, Vince, Adriana, Waheed, Yasir, Waked, Imam, Walsh, Nicholas, Weis, Nina, Wong, Vincent W, Woodring, Joseph, Yaghi, Cesar, Yang, Hwai-I, Yang, Chung-Lin, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yusuf, Muhammed Aasim M, Zeuzem, Stefan, and Razavi, Homie

Published
2018
Full Text
View/download PDF

30. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

Author

Huang, Chung-Feng, Iio, Etsuko, Jun, Dae Won, Ogawa, Eiichi, Toyoda, Hidenori, Hsu, Yao-Chun, Haga, Hiroaki, Iwane, Shinji, Enomoto, Masaru, Lee, Dong Hyun, Wong, Grace, Liu, Chen-Hua, Tada, Toshifumi, Chuang, Wan-Long, Cheung, Ramsey, Hayashi, Jun, Tseng, Cheng-Hao, Yasuda, Satoshi, Tran, Sally, Kam, Leslie, Henry, Linda, Jeong, Jae Yoon, Nomura, Hideyuki, Park, Seung Ha, Nakamuta, Makoto, Huang, Jee-Fu, Tai, Chi-Ming, Lo, Gin-Ho, Lee, Mei-Hsuan, Yang, Hwai-I, Kao, Jia-Horng, Tamori, Akihiro, Eguchi, Yuichiro, Ueno, Yoshiyuki, Furusyo, Norihiro, Tanaka, Yasuhito, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2019
Full Text
View/download PDF

33. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Author

Blach, Sarah, Zeuzem, Stefan, Manns, Michael, Altraif, Ibrahim, Duberg, Ann-Sofi, Muljono, David H, Waked, Imam, Alavian, Seyed M, Lee, Mei-Hsuan, Negro, Francesco, Abaalkhail, Faisal, Abdou, Ahmed, Abdulla, Maheeba, Rached, Antoine Abou, Aho, Inka, Akarca, Ulus, Al Ghazzawi, Imad, Al Kaabi, Saad, Al Lawati, Faryal, Al Namaani, Khalid, Al Serkal, Youssif, Al-Busafi, Said A, Al-Dabal, Layla, Aleman, Soo, Alghamdi, Abdullah S, Aljumah, Abdulrahman A, Al-Romaihi, Hamad E, Andersson, Monique I, Arendt, Vic, Arkkila, Perttu, Assiri, Abdullah M, Baatarkhuu, Oidov, Bane, Abate, Ben-Ari, Ziv, Bergin, Colm, Bessone, Fernando, Bihl, Florian, Bizri, Abdul R, Blachier, Martin, Blasco, Antonio J, Mello, Carlos E Brandão, Bruggmann, Philip, Brunton, Cheryl R, Calinas, Filipe, Chan, Henry L Y, Chaudhry, Asad, Cheinquer, Hugo, Chen, Chien-Jen, Chien, Rong-Nan, Choi, Moon Seok, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Clausen, Mette R, Cramp, Matthew E, Craxi, Antonio, Croes, Esther A, Dalgard, Olav, Daruich, Jorge R, de Ledinghen, Victor, Dore, Gregory J, El-Sayed, Manal H, Ergör, Gul, Esmat, Gamal, Estes, Chris, Falconer, Karolin, Farag, Elmoubashar, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, Gane, Ed, García-Samaniego, Javier, Khan, Amir Ghafoor, Gountas, Ilias, Goldis, Adrian, Gottfredsson, Magnús, Grebely, Jason, Gschwantler, Michael, Pessôa, Mário Guimarães, Gunter, Jessie, Hajarizadeh, Behzad, Hajelssedig, Omer, Hamid, Saeed, Hamoudi, Waseem, Hatzakis, Angelos, Himatt, Sayed M, Hofer, Harald, Hrstic, Irena, Hui, Yee-Tak, Hunyady, Bela, Idilman, Ramazan, Jafri, Wasim, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jeruma, Agita, Jonasson, Jón G, Kamel, Yasser, Kao, Jia-Horng, Kaymakoglu, Sabahattin, Kershenobich, David, Khamis, Jawad, Kim, Young S, Kondili, Loreta, Koutoubi, Zaher, Krajden, Mel, Krarup, Henrik, Lai, Moon-sing, Laleman, Wim, Lao, Wai-cheung, Lavanchy, Daniel, Lázaro, Pablo, Leleu, Henri, Lesi, Olufunmilayo, Lesmana, Laurentius A, Li, Michael, Liakina, Valentina, Lim, Young-Suk, Luksic, Boris, Mahomed, Adam, Maimets, Matti, Makara, Mihály, Malu, Abraham O, Marinho, Rui T, Marotta, Paul, Mauss, Stefan, Memon, Muhammad S, Correa, Maria C Mendes, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Moreno, Christophe, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Nde, Helen, Njouom, Richard, Nonkovic, Diana, Norris, Suzanne, Obekpa, Solomon, Oguche, Stephen, Olafsson, Sigurður, Oltman, Marian, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Øvrehus, Anne L H, Owusu-Ofori, Shirley, Oyunsuren, Tsendsuren S, Papatheodoridis, George, Pasini, Ken, Peltekian, Kevork M, Phillips, Richard O, Pimenov, Nikolay, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Ridruejo, Ezequiel, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Rosenberg, William M, Roudot-Thoraval, Françoise, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Avila, Juan F Sanchez, Saraswat, Vivek, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shevaldin, Anatoly, Shiha, Gamal E, Sievert, William, Sonderup, Mark, Souliotis, Kyriakos, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Stauber, Rudolf E, Stedman, Catherine, Struck, Daniel, Su, Tung-Hung, Sypsa, Vana, Tan, Soek-Siam, Tanaka, Junko, Thompson, Alexander J, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jonas, Van Damme, Pierre, van der Meer, Adriaan J, van Thiel, Ingo, Van Vlierberghe, Hans, Vince, Adriana, Vogel, Wolfgang, Wedemeyer, Heiner, Weis, Nina, Wong, Vincent WS, Yaghi, Cesar, Yosry, Ayman, Yuen, Man-fung, Yunihastuti, Evy, Yusuf, Aasim, Zuckerman, Eli, and Razavi, Homie

Published
2017
Full Text
View/download PDF

35. Genetic Susceptibility of HLA Alleles to Non-Steroidal Anti-Inflammatory Drug Hypersensitivity in the Taiwanese Population.

Author

Chang, Szu-Ling, Lai, Chih-Hung, Lin, Guan-Cheng, Chen, Yi-Ming, Lee, Mei-Hsuan, Hsu, Han-Shui, and Chen, I-Chieh

Subjects
TAIWANESE people, DRUG allergy, DRUG side effects, ANTI-inflammatory agents, HLA histocompatibility antigens
Abstract

Background: Human leukocyte antigen (HLA) genes are important in many immune processes and contribute to many adverse drug reactions. Whether genetic variations in the HLA region are associated with non-steroid anti-inflammatory drug (NSAID) hypersensitivity remains uncertain. Therefore, the aim of our study was to identify HLA genetic variations in patients with NSAID hypersensitivity in the Taiwanese population. Methods: This hospital-based, retrospective case-control study enrolled 37,156 participants with NSAID exposure from the Taiwan Precision Medicine Initiative (TPMI), who were all genotyped and imputed to fine map HLA typing. Our study assigned 1217 cases to the NSAID allergy group and 12,170 controls to a matched group. Logistic regression analyses were utilized to explore associations between HLA alleles and NSAID hypersensitivity. Results: Overall, 13,387 patients were genotyped for eight major HLA alleles. Allele frequencies were different between the two groups. In the NSAID allergy group, the genotype frequencies of HLA-A*02:01, HLA-A*34:01, and HLA-DQA1*06:01 were found to be markedly elevated compared to the control group, a significance that persisted even after applying the Bonferroni correction. Furthermore, the risk of NSAID allergy demonstrated a significant association with HLA-A*02:01 (OR = 1.29, p < 0.001) and HLA-A*34:01 (OR = 9.90, p = 0.001), in comparison to their respective counterparts. Notably, the genotype frequency of HLA-B*46:01 exhibited a significant increase in the severe allergy group when compared with the mild allergy group. Conclusions: We identified HLA genotypes linked to the onset and severity of NSAID hypersensitivity. Our findings establish a basis for precision prescription in future clinical applications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review.

Author

Hsu, Christine C, Gopalakrishna, Harish, Mironova, Maria, Lee, Mei-Hsuan, Chen, Chien-Jen, Yang, Hwai-I, Wiese, Manfred, Chang, Kyong-Mi, Wright, Elizabeth C, Abijo, Tomilowo, Feld, Jordan J, and Kaplan, David E

Subjects
ONLINE information services, MEDICAL databases, CHRONIC hepatitis C, MEDICAL information storage & retrieval systems, META-analysis, CONFIDENCE intervals, SYSTEMATIC reviews, HEPATITIS C, ANTIVIRAL agents, TREATMENT effectiveness, COMPARATIVE studies, DESCRIPTIVE statistics, MEDLINE, DATA analysis software, DISEASE remission, HEPATOCELLULAR carcinoma, DISEASE risk factors, DISEASE complications
Abstract

In a hepatitis C virus (HCV)–controlled human infection model (CHIM), healthy volunteers are inoculated with HCV and then treated. Residual hepatocellular carcinoma (HCC) risk after viral clearance is an important consideration when evaluating the CHIM. We estimate HCC risk in spontaneously cleared HCV and in noncirrhosis after sustained virological response (SVR) to HCV treatment in a systematic review and using data from 3 cohorts: German anti-D, Taiwan, and US Veterans Affairs (VA). For noncirrhosis SVR, the overall HCC rate is 0.33 per 100 patient-years in meta-analysis. HCC rates for the German, Taiwan, and US Veterans Affairs cohorts are 0, 0.14, and 0.02 per 100 patient-years, respectively. Past hepatitis B virus exposure was not accounted for in the Taiwan cohort, while VA patients were likely tested based on liver disease/risk factors, which may confound HCC outcomes. The German cohort with no HCC after 44 years is most comparable to the CHIM participants. Although it is difficult to precisely estimate HCC risk from an HCV CHIM, the data suggest the risk to be very low or negligible. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL‐HBV and REVEAL‐HCV cohort studies.

Author

Petrick, Jessica L., Florio, Andrea A., Zen, Jane, Wang, Yanyu, Gewirtz, Andrew T., Pfeiffer, Ruth M., Loftus, Sarah, Inglefield, Jon, Koshiol, Jill, Yang, Baiyu, Yu, Kelly, Hildesheim, Allan, Chen, Chien‐Jen, Yang, Hwai‐I, Lee, Mei‐Hsuan, and McGlynn, Katherine A.

Subjects
DISEASE risk factors, LIVER diseases, COHORT analysis, LIVER cancer, BIOMARKERS, CHRONIC hepatitis B
Abstract

Gut barrier dysfunction can result in the liver being exposed to an elevated level of gut‐derived bacterial products via portal circulation. Growing evidence suggests that systemic exposure to these bacterial products promotes liver diseases including hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). However, prospective studies have not examined the association between biomarkers of gut barrier dysfunction and HCC risk in a population of hepatitis B or C viral (HBV/HCV) carriers. We investigated whether prediagnostic, circulating biomarkers of gut barrier dysfunction were associated with HCC risk, using the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer (REVEAL)‐HBV and REVEAL‐HCV cohorts from Taiwan. REVEAL‐HBV included 185 cases and 161 matched controls, and REVEAL‐HCV 96 cases and 96 matched controls. The biomarkers quantitated were immunoglobulin A (IgA), IgG, and IgM against lipopolysaccharide (LPS) and flagellin, soluble CD14 (an LPS coreceptor), and LPS‐binding protein (LBP). Odds ratios (ORs) and 95% confidence intervals (CIs) for associations between biomarker levels and HCC were calculated using multivariable‐adjusted logistic regression. A doubling of the circulating levels of antiflagellin IgA or LBP was associated with a 76% to 93% increased risk of HBV‐related HCC (OR per one unit change in log2 antiflagellin IgA = 1.76, 95% CI: 1.06‐2.93; OR for LBP = 1.93, 95% CI: 1.10‐3.38). None of the other markers were associated with an increased risk of HBV‐related or HCV‐related HCC. Results were similar when cases diagnosed in the first 5 years of follow‐up were excluded. Our findings contribute to understanding the interplay of gut barrier dysfunction and primary liver cancer etiology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Effects of Thinking Style and Spatial Ability on Anchoring Behavior in Geographic Information Systems

Author

Wang, Dai-Yi, Lee, Mei-Hsuan, and Sun, Chuen-Tsai

Abstract

The authors propose an instructional use for Google Earth (a GIS application) as an anchoring tool for knowledge integration. Google Earth can be used to support student explorations of world geography based on Wikipedia articles on earth science and history topics. We asked 66 Taiwanese high-school freshmen to make place marks with explanatory notes and summaries (known as anchors) to serve as geographic references; they used anchors that were predefined by their teacher for subsequent geographic searches. Our investigation focused on the processes used to create anchors, how the students used anchors to perform search tasks, and the roles of thinking style and spatial ability on learning processes and performance. The 671 generated anchors were categorized as direct, indirect, symbolic, temporal, spatial, and challenging. According to our results, students with legislative thinking style tendencies created the largest number of anchors but rarely used them for subsequent search tasks; executive-style students tended to make symbolic and temporal spatial geographic references and regularly used the teacher-created anchors and the anchors created by judicial-style students were evenly distributed across all categories. In addition, low-spatial ability students tended to create direct geographic references and to use predefined anchors for all problem types.

Published
2013

49. Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR -Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib.

Author

Tsai, Ming-Ju, Hung, Jen-Yu, Ma, Juei-Yang, Tsai, Yu-Chen, Wu, Kuan-Li, Lee, Mei-Hsuan, Kuo, Chia-Yu, Chuang, Cheng-Hao, Lee, Tai-Huang, Lee, Yen-Lung, Huang, Chun-Ming, Shen, Mei-Chiou, Yang, Chih-Jen, and Chong, Inn-Wen

Subjects
ADENOCARCINOMA, LUNG cancer, HOSPITALS, CONFIDENCE intervals, EPIDERMAL growth factor receptors, MULTIVARIATE analysis, RETROSPECTIVE studies, LUNG tumors, AFATINIB, TREATMENT effectiveness, RESEARCH funding, PROBABILITY theory
Abstract

Simple Summary: Afatinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used to treat patients with advanced EGFR-mutant lung cancer. In this study, we retrospectively enrolled patients with lung adenocarcinomas harboring susceptible EGFR mutations, who were diagnosed and treated with first-line afatinib in three Kaohsiung Medical University-affiliated hospitals. Patients who received local consolidative therapy (LCT) had a significantly longer PFS than those who did not. Patients who received LCT also had significantly longer OS. Multivariable analysis showed LCT was an independent prognostic factor for improved PFS and OS. The analyses using propensity score-weighting showed consistent results. We conclude that LCT may improve clinical outcomes, in terms of PFS and OS, in patients with advanced EGFR-mutant lung adenocarcinomas who are treated with first-line afatinib. Further large-scale prospective trials are warranted. Afatinib is an irreversible tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), which is utilized for the treatment of patients with advanced lung cancer that harbors EGFR mutations. No studies have evaluated the clinical efficacy of LCT in patients treated with first-line afatinib. In this study, we retrospectively enrolled patients with advanced lung adenocarcinomas harboring susceptible EGFR mutations who were diagnosed and treated with first-line afatinib in three hospitals. A total of 254 patients were enrolled, including 30 (12%) patients who received LCT (15 patients received definitive radiotherapy for the primary lung mass and 15 patients received curative surgery). Patients who received LCT had a significantly longer PFS than those who did not (median PFS: 32.8 vs. 14.5 months, p = 0.0008). Patients who received LCT had significantly longer OS than those who did not (median OS: 67.1 vs. 34.5 months, p = 0.0011). Multivariable analysis showed LCT was an independent prognostic factor for improved PFS (adjusted hazard ratio [aHR] [95% confidence interval (CI)]: 0.44 [0.26–0.73], p = 0.0016) and OS (aHR [95% CI]: 0.26 [0.12–0.54], p = 0.0004). The analyses using propensity score-weighting showed consistent results. We conclude that LCT may improve clinical outcomes, in terms of PFS and OS, in patients with advanced EGFR-mutant lung adenocarcinomas who are treated with first-line afatinib. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Association of periodontal disease with migraine: A large‐scale community‐based cross‐sectional study.

Author

Chen, Yen‐Ju, Hu, Kai‐Fang, Chan, Chi, Huang, Claire, Huang, Yu‐Han, Wang, Yen‐Feng, Wang, Shuu‐Jiun, Chen, Shih‐Pin, and Lee, Mei‐Hsuan

Subjects
MIGRAINE risk factors, CONFIDENCE intervals, CROSS-sectional method, SINGLE nucleotide polymorphisms, PERIODONTAL disease, RISK assessment, INDEPENDENT living, GENOTYPES, DESCRIPTIVE statistics, RESEARCH funding, ODDS ratio, DISEASE complications
Abstract

Background: Periodontal disease may drive a systemic inflammatory response that triggers migraine; however, the association between periodontal disease and migraine has rarely been investigated in a community‐based setting. Methods: This cross‐sectional study included 66,109 participants aged 30 to 70 years from Taiwan Biobank (TWB). A structured questionnaire was administered to participants, who were also subjected to whole‐genome single nucleotide polymorphism genotyping using the customized Axiom–TWB array. To identify subjects with periodontal disease and migraine, the computerized linkage of data obtained from TWB and the National Health Insurance Research Database was performed. Participants were evaluated for their genetic predisposition to migraine using a polygenic risk score. We examined and estimated the magnitude of associations between periodontal disease and migraine. Results: In this study, 4618 (4618/66,109; 7%) participants with migraine and 61,491 (61,491/66,109; 83%) participants without migraine were included. Participants with migraine exhibited a higher prevalence of periodontal disease than participants without migraine (4324/4618; 94% vs. 56,036/61,491; 91%). A significant positive association was observed between periodontal disease and migraine, with an adjusted odds ratio (ORadj) of 1.40 (95% confidence interval [CI] = 1.24–1.59; p < 0.001). The association remained consistent even after excluding participants with other comorbidities (ORadj = 1.34; 95% CI = 1.16–1.55; p < 0.001). Moreover, the positive association between periodontal disease and migraine remained significant across the subgroups of age, sex, other comorbidities, and classified polygenic risk scores of migraine, with the ORadj ranging from 1.26 to 1.78. Conclusions: A significant positive association was observed between periodontal disease and migraine. Future studies need to explore the biological mechanisms of how periodontal disease might affect migraine. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results